4月3日，荣昌生物今日收盘43.78元，下跌1.40%，最新市净率12.00，总市值238.31亿元。
截至2024年年报，共有265家机构持仓荣昌生物，其中基金262家、其他3家，合计持股数9245.91万股，持股市值27.84亿元。
荣昌生物制药(烟台)股份有限公司的主营业务是开发与商业化创新、有特色的同类首创（first-in-class）与同类最佳（best-in-class）生物药，以创造药物临床价值为导向，为自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域提供安全、有效、可及的临床解决方案，以满足大量尚未被满足的临床需求。公司的主要产品是泰它西普（RC18）、维迪西妥单抗（RC48）、RC28、RC88、RC148、RC278。
最新一期业绩显示，2024年年报，公司实现营业收入17.17亿元，同比58.54%；净利润-1468360802.55元，同比2.84%，销售毛利率80.36%。
| 序号 | 股票简称 | PE(TTM) | PE(静) | 市净率 | 总市值(元) |
| 20 | 荣昌生物 | -16.23 | -16.23 | 12.00 | 238.31亿 |
| 行业平均 | 42.13 | 41.27 | 8.63 | 185.79亿 | |
| 行业中值 | 37.66 | 34.75 | 2.99 | 77.63亿 | |
| 1 | 万泰生物 | -279.67 | 65.91 | 6.62 | 822.33亿 |
| 2 | 仁度生物 | -208.42 | -208.42 | 1.66 | 15.38亿 |
| 3 | 诺思兰德 | -90.82 | -90.82 | 12.01 | 41.03亿 |
| 4 | 诺诚健华 | -73.92 | -73.92 | 4.84 | 325.72亿 |
| 5 | 百济神州 | -70.54 | -70.54 | 14.53 | 3511.80亿 |
| 6 | 赛升药业 | -61.35 | -61.35 | 1.26 | 42.24亿 |
| 7 | 四环生物 | -57.48 | -35.56 | 5.73 | 26.77亿 |
| 8 | 益方生物 | -46.15 | -46.15 | 6.53 | 113.35亿 |
| 9 | 近岸蛋白 | -43.69 | -43.69 | 1.12 | 23.94亿 |
| 10 | 双成药业 | -40.53 | -69.47 | 8.12 | 35.25亿 |
| 11 | 康希诺 | -39.58 | -39.58 | 3.05 | 149.98亿 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.